IsoRay, Inc. (DE) (ISR): Price and Financial Metrics
ISR Price/Volume Stats
| Current price | $0.38 | 52-week high | $0.45 |
| Prev. close | $0.38 | 52-week low | $0.19 |
| Day low | $0.36 | Volume | 145,000 |
| Day high | $0.39 | Avg. volume | 290,697 |
| 50-day MA | $0.32 | Dividend yield | N/A |
| 200-day MA | $0.33 | Market Cap | 54.57M |
ISR Stock Price Chart Interactive Chart >
IsoRay, Inc. (DE) (ISR) Company Bio
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.
Latest ISR News From Around the Web
Below are the latest news stories about ISORAY INC that investors may wish to consider to help them evaluate ISR as an investment opportunity.
IsoRay (ISR) Reports Q2 Loss, Misses Revenue EstimatesIsoRay (ISR) delivered earnings and revenue surprises of -100% and 56.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022Fiscal Calendar Year Changes from June to December Year EndRICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended Decem |
Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy and its newly merged partner Viewpoint Molecular Targeting, Inc., today announced that they are now doing business a |
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology MedicineRICHLAND, Wash. & CORALVILLE, Iowa, February 06, 2023--Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc. The combined companies’ focus will be the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so that precision, targeted medical doses are delivered directly to cancer patient tumor site |
Isoray Announces Results of Fiscal 2023 Annual Meeting of StockholdersStockholders Approve Proposal One Clearing Way for Consummation of MergerRICHLAND, Wash., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced the results of its adjourned Fiscal 2023 Annual Meeting of Stockholders which was held on January 27, 2023. The stockholders approved Proposal One which amends the Company’s Certificate of Incorporation |
ISR Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -44.28% |
| 5-year | 20.60% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -36.28% |
| 2021 | -13.82% |
| 2020 | -27.93% |
| 2019 | 108.13% |
Continue Researching ISR
Want to do more research on Isoray Inc's stock and its price? Try the links below:Isoray Inc (ISR) Stock Price | Nasdaq
Isoray Inc (ISR) Stock Quote, History and News - Yahoo Finance
Isoray Inc (ISR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...